25.03.2024 • NewsSchottSchott Pharmainvestment

Schott Pharma to Build New US Prefillable Syringe Manufacturing Facility

In a move to triple its production of glass and polymer syringes for the US market by 2030, Germany’s Schott Pharma announced plans to build its first US facility to manufacture prefillable polymer syringes that meet the need for deep-cold storage and transportation of mRNA medications.

In addition, the site will have the capability to produce glass prefillable syringes for GLP-1 therapies, for example to treat diseases such as diabetes or obesity.

The project, Schott Pharma said, will create 401 jobs and include a total investment of $371 million, with groundbreaking expected by the end of 2024, and projected operations starting in 2027.

“As drug manufacturers develop and expand the use of mRNA, GLP-1, and other biologic therapies that require precise drug stability and storage properties, Schott Pharma will be able to fill those orders quickly and efficiently here in the US,” said Andreas Reisse, CEO of Schott Pharma. “The impact of this facility will go far beyond local job creation in North Carolina and will relieve stress on the entire pharmaceutical industry supply chain,” Reisse added.

Rendering of new planned Schott Pharma manufacturing facility in Wilson, North...
Rendering of new planned Schott Pharma manufacturing facility in Wilson, North Carolina. Source: Schott Pharma

Company

Logo:

Schott Pharma


Mainz
Germany

Company contact







Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.